The Efficacy and Safety of PD-1PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis
المؤلفون المشاركون
Nie, Run-Cong
Zhao, Chong-Bang
Xia, Xiao-Wei
Luo, Ying-Shan
Wu, Ting
Zhou, Zhi-Wei
Yuan, Shu-Qiang
Wang, Yun
Li, Yuan-Fang
المصدر
العدد
المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-10، 10ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2020-05-06
دولة النشر
مصر
عدد الصفحات
10
التخصصات الرئيسية
الملخص EN
Objectives.
To evaluate the efficacy of immuno-oncology combinational therapy (IOCT) versus monotherapy with programmed cell death 1 (PD-1) or PD-ligand 1 (PD-L1) inhibitors or conventional therapies, i.e., non-IOCT, in patients with advanced solid tumors.
Methods.
We systematically searched the PubMed, Embase, and Cochrane Library databases from January 2015 to October 2018 for eligible studies.
We included randomized trials of IOCT with available hazard ratios (HR) for death.
The random effects model was used to calculate pooled HR for death; heterogeneity was assessed using I2 statistics.
The main outcome measure was overall survival (OS).
Results.
After screening 483 relevant articles, we identified twelve trials comprising 5388 patients for quantitative analysis.
IOCT-treated patients had significantly higher tumor response rate (relative risk (RR): 2.51, 95% confidence interval (CI): 1.82-3.47), prolonged progression-free survival (HR 0.62, 95% CI: 0.53-0.74), and OS (HR 0.69, 95% CI: 0.61-0.78), compared with non-IOCT–treated patients.
Sensitivity analyses also demonstrated the OS advantage of IOCT across different combination modalities, intervention agents, malignancy types, and PD-L1 expression (all P<0.05).
Notably, there were higher odds of high-grade (grade≥3) adverse events with IOCT (RR: 1.81, 95% CI: 1.13-2.90), but the risk of treatment-related death (RR: 1.16, 95% CI: 0.84–1.60) was not increased compared with non-IOCT.
Conclusions.
IOCT is a preferable treatment option over PD-1/PD-L1 inhibitor monotherapy and conventional therapy for patients with advanced solid tumors.
However, we should note the increased incidence rate of high-grade AEs in IOCT.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Nie, Run-Cong& Zhao, Chong-Bang& Xia, Xiao-Wei& Luo, Ying-Shan& Wu, Ting& Zhou, Zhi-Wei…[et al.]. 2020. The Efficacy and Safety of PD-1PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis. BioMed Research International،Vol. 2020, no. 2020, pp.1-10.
https://search.emarefa.net/detail/BIM-1134423
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Nie, Run-Cong…[et al.]. The Efficacy and Safety of PD-1PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis. BioMed Research International No. 2020 (2020), pp.1-10.
https://search.emarefa.net/detail/BIM-1134423
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Nie, Run-Cong& Zhao, Chong-Bang& Xia, Xiao-Wei& Luo, Ying-Shan& Wu, Ting& Zhou, Zhi-Wei…[et al.]. The Efficacy and Safety of PD-1PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis. BioMed Research International. 2020. Vol. 2020, no. 2020, pp.1-10.
https://search.emarefa.net/detail/BIM-1134423
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1134423
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر